Kura Oncology (NASDAQ:KURA – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04, Briefing.com reports. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.53) EPS.
Kura Oncology Trading Down 0.8 %
Shares of KURA stock traded down $0.15 on Friday, reaching $18.97. 1,107,395 shares of the company’s stock were exchanged, compared to its average volume of 1,047,496. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.45 billion, a PE ratio of -8.74 and a beta of 0.88. The company’s fifty day simple moving average is $20.74 and its 200 day simple moving average is $20.69.
Insider Buying and Selling
In related news, insider Teresa Brophy Bair sold 2,615 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the completion of the sale, the insider now directly owns 68,979 shares of the company’s stock, valued at approximately $1,527,884.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
View Our Latest Report on KURA
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Stories
- Five stocks we like better than Kura Oncology
- 3 Warren Buffett Stocks to Buy Now
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Using the MarketBeat Dividend Yield Calculator
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- 3 Small Caps With Big Return Potential
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.